Back to Journals » Therapeutics and Clinical Risk Management » Volume 14

Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson's disease

Authors Sharma VD, Lyons KE, Pahwa R

Received 25 January 2018

Accepted for publication 16 March 2018

Published 12 April 2018 Volume 2018:14 Pages 665—673

DOI https://doi.org/10.2147/TCRM.S144481

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Justinn Cochran

Peer reviewer comments 3

Editor who approved publication: Professor Garry Walsh


Vibhash D Sharma, Kelly E Lyons, Rajesh Pahwa

Department of Neurology, University of Kansas Medical Center, Kansas City, KS, USA

Abstract: Levodopa-induced dyskinesia (LID) is a common motor complication in patients with Parkinson’s disease on chronic levodopa therapy. The management of LID is important as dyskinesia can be disabling and impair quality of life. Currently, there are limited treatment options for the medical management of LID. Amantadine extended-release capsules (Gocovri™) is the first medication that received US Food and Drug Administration approval for the treatment of LID. The following is a review of the pharmacodynamics, efficacy and safety profile, and current state of treatment of amantadine for LID.

Keywords: Parkinson’s disease, levodopa-induced dyskinesia, amantadine, amantadine extended-release

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]